首站-论文投稿智能助手
典型文献
Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro
文献摘要:
Dear Editor, The coronavirus disease 2019(COVID-19)outbreak,has spread across the world(Wu et al.,2020).The causative agent of COVID-19,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),is highly pathogenic and infectious,which become a major public health hazard that has had a devastating social and economic impact worldwide(Li Q.Q.et al.,2020). Variants of the virus have emerged that behave differently(CDC 2021;Gobeil et al.,2020;Leung et al.,2021).Some of them show increased infectivity(Li Q.et al.,2020;Zhang et al.,2020)and may escape from neutralizing antibodies(Weisblum et al.,2020).Various vaccines have been developed and marketed for COVID-19.However,there is a shortage of specific drugs to treat this novel virus and there is an urgent need for effective broad-spectrum anti-viral drugs to treat COVID-19 and its variants.
文献关键词:
作者姓名:
Danrong Shi;Keda Chen;Xiangyun Lu;Linfang Cheng;Tianhao Weng;Fumin Liu;Nanping Wu;Lanjuan Li;Hangping Yao
作者机构:
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases,National Clinical Research Center for Infectious Diseases,National Medical Center for Infectious Diseases,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou,310003,China;Shulan International Medical College,Zhejiang Shuren University,Hangzhou,310015,China
文献出处:
引用格式:
[1]Danrong Shi;Keda Chen;Xiangyun Lu;Linfang Cheng;Tianhao Weng;Fumin Liu;Nanping Wu;Lanjuan Li;Hangping Yao-.Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro)[J].中国病毒学,2022(02):295-298
A类:
Variants,Gobeil,Leung,Weisblum
B类:
Recombinant,human,interferon,1b,inhibits,SARS,CoV,better,than,2b,vitro,Dear,Editor, The,coronavirus,disease,outbreak,has,spread,across,Wu,causative,agent,severe,acute,respiratory,syndrome,highly,pathogenic,infectious,which,become,major,public,health,hazard,that,had,devastating,social,economic,impact,worldwide,Li,emerged,behave,differently,CDC,Some,them,show,increased,infectivity,Zhang,may,escape,from,neutralizing,antibodies,Various,vaccines,been,developed,marketed,However,there,shortage,specific,drugs,treat,this,novel,urgent,need,effective,broad,spectrum,viral,variants
AB值:
0.626835
相似文献
Comprehensive analysis of RNA-seq and whole genome sequencing data reveals no evidence for SARS-CoV-2 integrating into host genome
Yu-Sheng Chen;Shuaiyao Lu;Bing Zhang;Tingfu Du;Wen-Jie Li;Meng Lei;Yanan Zhou;Yong Zhang;Penghui Liu;Yong-Qiao Sun;Yong-Liang Zhao;Ying Yang;Xiaozhong Peng;Yun-Gui Yang-CAS Key Laboratory of Genomic and Precision Medicine,Col-laborative Innovation Center of Genetics and Development,College of Future Technology,Beijing Institute of Genomics,Chinese Academy of Sciences,Beijing 100101,China;China National Center for Bioinformation,Beijing 100101,China;Institute of Stem Cell and Regeneration,Chinese Academy of Sciences,Beijing 100101,China;National Kunming High-level Biosafety Primate Research Center,Institute of Medical Biology,Chinese Academy of Medical Sciences and Peking Union Medical College,Kunming 650031,China;University of Chinese Academy of Sciences,Beijing 100049,China;State Key Laboratory of Medical Molecular Biology,Department of Molecular Biology and Biochemistry,Institute of Basic Medical Sciences,Medical Primate Research Center,Neuroscience Cen-ter,Chinese Academy of Medical Sciences,School of Basic Medicine Peking,Union Medical College,Beijing 100005,China
Low-dose chloroquine treatment extends the lifespan of aged rats
Wei Li;Zhiran Zou;Yusheng Cai;Kuan Yang;Si Wang;Zunpeng Liu;Lingling Geng;Qun Chu;Zhejun Ji;Piu Chan;Guang-Hui Liu;Moshi Song;Jing Qu;Weiqi Zhang-Advanced Innovation Center for Human Brain Protection,National Clinical Research Center for Geriatric Disorders,Xuanwu Hospital Capital Medical University,Beijing 100053,China;Aging Translational Medicine Center,Xuanwu Hospital,Capital Medical University,Beijing 100053,China;State Key Laboratory of Membrane Biology,Institute of Zoology,Chinese Academy of Sciences,Beijing 100101,China;Institute for Stem Cell and Regeneration,Chinese Academy of Sciences,Beijing 100101,China;University of Chinese Academy of Sciences,Beijing 100049,China;Beijing Institute for Stem Cell and Regenerative Medicine,Beijing 100101,China;CAS Key Laboratory of Genomic and Precision Medicine,Beijing Institute of Genomics,Chinese Academy of Sciences,Beijing 100101,China;China National Center for Bioinformation,Beijing 100101,China;Sino-Danish College,University of Chinese Academy of Sciences,Beijing 101408,China;Sino-Danish Center for Education and Research,Beijing 101408,China;Chongqing Renji Hospital,University of Chinese Academy of Sciences,Chongqing 400062,China;State Key Laboratory of Stem Cell and Reproductive Biology,Institute of Zoology,Chinese Academy of Sciences,Beijing 100101,China
Large-scale chemical screen identifies Gallic acid as a geroprotector for human stem cells
Hezhen Shan;Lingling Geng;Xiaoyu Jiang;Moshi Song;Jianxun Wang;Zunpeng Liu;Xiao Zhuo;Zeming Wu;Jianli Hu;Zhejun Ji;Si Wang;Piu Chan;Jing Qu;Weiqi Zhang;Guang-Hui Liu-State Key Laboratory of Membrane Biology,Institute of Zoology,Chinese Academy of Sciences,Beijing 100101,China;School of Life Sciences,Beijing University of Chinese Medicine,Beijing 100029,China;Advanced Innovation Center for Human Brain Protection,National Clinical Research Center for Geriatric Disorders,Xuanwu Hospital Capital Medical University,Beijing 100053,China;Aging Translational Medicine Center,Xuanwu Hospital,Capital Medical University,Beijing 100053,China;University of Chinese Academy of Sciences,Beijing 100049,China;Beijing Institute for Stem Cell and Regenerative Medicine,Beijing 100101,China;State Key Laboratory of Stem Cell and Reproductive Biology,Institute of Zoology,Chinese Academy of Sciences,Beijing 100101,China;CAS Key Laboratory of Genomic and Precision Medicine,Beijing Institute of Genomics,Chinese Academy of Sciences,Beijing 100101,China;China National Center for Bioinformation,Beijing 100101,China;Institute for Stem Cell and Regeneration,Chinese Academy of Sciences,Beijing 100101,China;Sino-Danish College,University of Chinese Academy of Sciences,Beijing 101408,China
Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant
Na-Na Zhang;Rong-Rong Zhang;Yi-Fei Zhang;Kai Ji;Xiao-Chuan Xiong;Qian-Shan Qin;Peng Gao;Xi-Shan Lu;Hang-Yu Zhou;Hai-Feng Song;Bo Ying;Cheng-Feng Qin-Department of Virology,State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;School of Medicine,Tsinghua University,Beijing,China;Kunming University of Science and Technology,Kunming,Yunnan,China;Suzhou Abogen Biosciences Co.,Ltd.,Suzhou,Jiangsu,China;School of Life Sciences,Fujian Agriculture and Forestry University,Fuzhou,Fujian,China;Institute of Systems Medicine,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo
Mengjiao Li;Zi-Wei Ye;Kaiming Tang;Liang Guo;Wenwen Bi;Yuyuan Zhang;Yan-dong Tang;Guoguang Rong;Mohamad Sawan;Xin Yin;Ren Sun;Shuofeng Yuan;Bobo Dang-Fudan University,Shanghai,China;Key Laboratory of Structural Biology of Zhejiang Province,School of Life Sciences,Westlake University,Hangzhou,Zhejiang,China;Center for Infectious Disease Research,Westlake Laboratory of Life Sciences and Biomedicine,Hangzhou,Zhejiang,China;Institute of Biology,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;Department of Microbiology,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Emerging Infectious Diseases,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China;State Key Laboratory of Veterinary Biotechnology,Harbin Veterinary Research Institute,Chinese Academy of Agricultural Sciences,Harbin,China;CenBRAIN Lab.,School of Engineering,Westlake University,Hangzhou,Zhejiang,China;CenBRAIN Lab.,Westlake Institute for Advanced Study,Hangzhou,Zhejiang,China;School of Biomedical Sciences,Li Ka Shing Faculty of Medicine,The University of Hong Kong,Pokfulam,Hong Kong,China
Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
Jun Lan;Xinheng He;Yifei Ren;Ziyi Wang;Huan Zhou;Shilong Fan;Chenyou Zhu;Dongsheng Liu;Bin Shao;Tie-Yan Liu;Qisheng Wang;Linqi Zhang;Jiwan Ge;Tong Wang;Xinquan Wang-The Ministry of Education Key Laboratory of Protein Science,Beijing Advanced Innovation Center for Structural Biology,Beijing Frontier Research Center for Biological Structure,Collaborative Innovation Center for Biotherapy,School of Life Sciences,Tsinghua University,Beijing,China;Microsoft Research Asia,Beijing,China;Shanghai Synchrotron Radiation Facility,Shanghai Advanced Research Institute,Chinese Academy of Sciences,Shanghai,China;Department of Chemistry,Tsinghua University,Beijing,China;Center for Global Health and Infectious Diseases,Comprehensive AIDS Research Center,and Beijing Advanced Innovation Center for Structural Biology,School of Medicine,Tsinghua University,Beijing,China
Selection and structural bases of potent broadly neutralizing antibodies from 3-dose vaccinees that are highly effective against diverse SARS-CoV-2 variants,including Omicron sublineages
Lei Wang;Wangjun Fu;Linlin Bao;Zijing Jia;Yuxia Zhang;Yunjiao Zhou;Wei Wu;Jianbo Wu;Qianqian Zhang;Yidan Gao;Kang Wang;Qiao Wang;Chuan Qin;Xiangxi Wang-CAS Key Laboratory of Infection and Immunity,National Laboratory of Macromolecules,Institute of Biophysics,Chinese Academy of Sciences,Beijing,China;University of Chinese Academy of Sciences,Beijing,China;Key Laboratory of Human Disease Comparative Medicine,Chinese Ministry of Health,Beijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases,Institute of Laboratory Animal Science,Chinese Academy of Medical Sciences and Comparative Medicine Center,Peking Union Medical College,Beijing,China;Changping Laboratory,Beijing,China;Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS),Shanghai Institute of Infectious Disease and Biosecurity,Shanghai Frontiers Science Center of Pathogenic Microbes and Infection,School of Basic Medical Sciences,Shanghai Medical College,Fudan University,Shanghai,China
Safety and superior immunogenicity of heterologous boosting with an RBD-based SARS-CoV-2 mRNA vaccine in Chinese adults
Xiaoqiang Liu;Yuhua Li;Zhongfang Wang;Shouchun Cao;Weijin Huang;Lin Yuan;Yi-Jiao Huang;Yan Zheng;Jingjing Chen;Bo Ying;Zuoyun Xiang;Jin Shi;Jincun Zhao;Zhen Huang;Cheng-Feng Qin-Yunnan Province Centre for Disease Control and Prevention,Kunming,Yunnan,China;National Institutes for Food and Drug Control,Beijing,China;Respiratory Medicine,Guangzhou Institute of Respiratory Health,Guangzhou,Guangdong,China;Walvax Biotechnology Co.,Ltd.,Kunming,Yunnan,China;State Key Laboratory of Pathogen and Biosecurity,Beijing Institute of Microbiology and Epidemiology,Academy of Military Medical Sciences,Beijing,China;Suzhou Abogen Biosciences Co.,Ltd,Suzhou,Jiangsu,China;Research Unit of Discovery and Tracing of Natural Focus Diseases,Chinese Academy of Medical Sciences,Beijing,China
A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding
Yingdan Wang;Wuqiang Zhan;Jiangyan Liu;Yanqun Wang;Xiang Zhang;Meng Zhang;Lin Han;Yunping Ma;Lu Lu;Yumei Wen;Zhenguo Chen;Jincun Zhao;Fan Wu;Lei Sun;Jinghe Huang-Key Laboratory of Medical Molecular Virology(MOE/NHC/CAMS)and Shanghai Institute of Infectious Disease and Biosecurity,Shanghai Fifth People's Hospital,Shanghai Public Health Clinical Center,Institutes of Biomedical Sciences,School of Basic Medical Sciences,Fudan University,Shanghai,China;Shanghai Immune Therapy Institute,Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital,Shanghai,China;State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China;Institute of Infectious Disease,Guangzhou Eighth People's Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。